ABK-356

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameABK-356
Drug Alias NameFGFR4 inhibitor (Abbisko Therapeutics)ABK-356
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 4 antagonists
TargetsFibroblast growth factor receptor 4
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesABbisko Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesABbisko Therapeutics Co Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksN/A